Compare FirstEnergy Corp. (FE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Tango Therapeutics Inc. — how do they compare? FirstEnergy Corp. trades at $45.72 (market cap $26.16B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: FirstEnergy Corp. is far larger — about 7× Tango Therapeutics Inc.'s market cap, and FirstEnergy Corp. pays a 4.11% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 72 Days and Tango Therapeutics Inc. for 0 Days on average.
| FE | TNGX | |
|---|---|---|
Market Cap | $26.16B | $3.75B |
Volume | 4,932,658 | 9,619,106 |
Sector | Utilities | Health |
52-Week High | $51.91 | $32.90 |
52-Week Low | $43.04 | $7.50 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $55.08B | $2.77B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $45.41, up 0.11% with a bullish technical signal. The stock shows mixed earnings performance with Q1 2026 beating expectations but Q4 2025 and Q2 2026 missing. Revenue grew to $15.09B in 2025 with a 6.86% net margin. Analyst consensus is Moderate Buy with a $51.00 price target, representing 12.3% upside. Recent developments include the Energize365 investment plan and consistent dividend payments.
FirstEnergy presents a stable utility investment with moderate growth potential through infrastructure investments. Key opportunities include the $36B Energize365 plan and rising data-center demand. Risks include high debt levels ($24.03B total debt), interest rate sensitivity, and regulatory challenges. The stock offers income through dividends but faces execution risks on capital projects.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
